Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion - PubMed

Affiliations

• PMID: 24760535
• DOI: 10.1530/EJE-14-0154

Review

Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion

David P Sonne et al. Eur J Endocrinol. 2014 Aug.

Abstract

Bile acid sequestrants have been used for decades for the treatment of hypercholesterolaemia. Sequestering of bile acids in the intestinal lumen interrupts enterohepatic recirculation of bile acids, which initiate feedback mechanisms on the conversion of cholesterol into bile acids in the liver, thereby lowering cholesterol concentrations in the circulation. In the early 1990s, it was observed that bile acid sequestrants improved glycaemic control in patients with type 2 diabetes. Subsequently, several studies confirmed the finding and recently - despite elusive mechanisms of action - bile acid sequestrants have been approved in the USA for the treatment of type 2 diabetes. Nowadays, bile acids are no longer labelled as simple detergents necessary for lipid digestion and absorption, but are increasingly recognised as metabolic regulators. They are potent hormones, work as signalling molecules on nuclear receptors and G protein-coupled receptors and trigger a myriad of signalling pathways in many target organs. The most described and well-known receptors activated by bile acids are the farnesoid X receptor (nuclear receptor) and the G protein-coupled cell membrane receptor TGR5. Besides controlling bile acid metabolism, these receptors are implicated in lipid, glucose and energy metabolism. Interestingly, activation of TGR5 on enteroendocrine L cells has been suggested to affect secretion of incretin hormones, particularly glucagon-like peptide 1 (GLP1 (GCG)). This review discusses the role of bile acid sequestrants in the treatment of type 2 diabetes, the possible mechanism of action and the role of bile acid-induced secretion of GLP1 via activation of TGR5.

Similar articles

• Beyond intestinal soap--bile acids in metabolic control.

  Kuipers F, Bloks VW, Groen AK. Kuipers F, et al. Nat Rev Endocrinol. 2014 Aug;10(8):488-98. doi: 10.1038/nrendo.2014.60. Epub 2014 May 13. Nat Rev Endocrinol. 2014. PMID: 24821328 Review.

• Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.

  Holst JJ, McGill MA. Holst JJ, et al. Clin Drug Investig. 2012 Jan;32(1):1-14. doi: 10.2165/11595370-000000000-00000. Clin Drug Investig. 2012. PMID: 27933595 Review.

• Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice.

  Potthoff MJ, Potts A, He T, Duarte JA, Taussig R, Mangelsdorf DJ, Kliewer SA, Burgess SC. Potthoff MJ, et al. Am J Physiol Gastrointest Liver Physiol. 2013 Feb 15;304(4):G371-80. doi: 10.1152/ajpgi.00400.2012. Epub 2012 Dec 20. Am J Physiol Gastrointest Liver Physiol. 2013. PMID: 23257920 Free PMC article.

• The Role of Bile Acids in Glucose Metabolism and Their Relation with Diabetes.

  González-Regueiro JA, Moreno-Castañeda L, Uribe M, Chávez-Tapia NC. González-Regueiro JA, et al. Ann Hepatol. 2017 Nov;16(Suppl. 1: s3-105.):16-21. doi: 10.5604/01.3001.0010.5672. Ann Hepatol. 2017. PMID: 29118282 Review.

• Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?

  Knop FK. Knop FK. Am J Physiol Endocrinol Metab. 2010 Jul;299(1):E10-3. doi: 10.1152/ajpendo.00137.2010. Epub 2010 Apr 27. Am J Physiol Endocrinol Metab. 2010. PMID: 20424139 Review.

Cited by

• Bile Acid Network and Vascular Calcification-Associated Diseases: Unraveling the Intricate Connections and Therapeutic Potential.

  Wang C, Ma Q, Yu X. Wang C, et al. Clin Interv Aging. 2023 Oct 21;18:1749-1767. doi: 10.2147/CIA.S431220. eCollection 2023. Clin Interv Aging. 2023. PMID: 37885621 Free PMC article. Review.

• Bile acids and their effects on diabetes.

  Rajani C, Jia W. Rajani C, et al. Front Med. 2018 Dec;12(6):608-623. doi: 10.1007/s11684-018-0644-x. Epub 2018 Oct 10. Front Med. 2018. PMID: 30306382 Review.

• Gut Microbiome-Linked Metabolites in the Pathobiology of Major Depression With or Without Anxiety-A Role for Bile Acids.

  MahmoudianDehkordi S, Bhattacharyya S, Brydges CR, Jia W, Fiehn O, Rush AJ, Dunlop BW, Kaddurah-Daouk R. MahmoudianDehkordi S, et al. Front Neurosci. 2022 Jul 20;16:937906. doi: 10.3389/fnins.2022.937906. eCollection 2022. Front Neurosci. 2022. PMID: 35937867 Free PMC article.

• Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.

  Li T, Chiang JYL. Li T, et al. Hepatobiliary Surg Nutr. 2020 Apr;9(2):152-169. doi: 10.21037/hbsn.2019.09.03. Hepatobiliary Surg Nutr. 2020. PMID: 32355674 Free PMC article. Review.

• HelixDiff, a Score-Based Diffusion Model for Generating All-Atom α-Helical Structures.

  Xie X, Valiente PA, Kim J, Kim PM. Xie X, et al. ACS Cent Sci. 2024 Apr 5;10(5):1001-1011. doi: 10.1021/acscentsci.3c01488. eCollection 2024 May 22. ACS Cent Sci. 2024. PMID: 38799672 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information